logo-loader
viewInnoCan Pharma

InnoCan Pharma planning to develop new line of CBD products and formulations with Tamar Technologies

Tamar Technologies is licensing InnoCan’s formulations and expertise as part of a cooperation agreement that the two companies signed in April 2019

InnoCan Pharma -
Tamar is InnoCan’s largest investor and owns or controls nearly 30.5 million shares

InnoCan Pharma Corporation (CSE:INNO) is developing a new line of CBD products and formulations in conjunction with major shareholder Tamar Technologies Ltd.

Tamar Technologies is licensing InnoCan’s formulations and expertise as part of a cooperation agreement that the two companies signed in April 2019.

The products will be developed by InnoCan under Tamar’s instructions and marketed under the Tamar brand, with Tamar taking responsibility for regulatory approvals, sales and marketing and distribution.

READ: InnoCan Pharma Corp announces tie-up with Tel Aviv University for new treatment for coronavirus pandemic

InnoCan will receive upfront payments for the development of new product formulations and sales-based royalties.

Tamar is InnoCan’s largest investor and owns or controls nearly 30.5 million shares, or 21.2% of the Canadian and Israeli company.

“The deep involvement of Tamar in InnoCan's activities, the close relationship between us and the advancements made by InnoCan since Tamar's initial investment have given Tamar the confidence to exercise a material portion of the agreement, leading to this collaboration,” InnoCan CEO Iris Bincovich said in a statement.

“This is a great sign of acknowledgment on the part of Tamar in our abilities to deliver formulations and products to the high standards expected by Tamar. The potential of the products developed is great and the collaboration will open a new potential revenue stream which, in parallel to InnoCan's own activity, will provide additional strength and diversification to InnoCan.”

Setting the standard for CBD

Ralph Bossino, Tamar’s CEO and a director at InnoCan, told shareholders that the firm believes consumers place their trust in companies that do not compromise on safety or quality.

“The vision behind Tamar's brand is to harness the power of CBD and to deliver effective, science backed products, utilizing natural and clean ingredients, that complement the lives and routines of consumers while setting a standard of reliability, quality, trust and transparency in the CBD market,” Bossino said in a statement.

Tamar’s decision to exercise its rights under the cooperation agreement represents the firm’s confidence in InnoCan’s ability to produce high-quality products and science-backed formulations, Bossino told shareholders.

In separate news, InnoCan also said that it has signed an investor relations agreement with Green Times Consulting Ltd, issuing the consultant over 1.4 shares priced at C$0.1725 per share.

InnoCan Pharma is a specialty pharmaceutical company that develops products that harness the unique properties of cannabinoids combined with smart delivery formulations.

Tamar Technologies invests in specialty biopharmaceutical advancements utilizing phytochemicals, focusing on strategic investments in leading companies in Israel, UK, and Canada.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: InnoCan Pharma

Price: 0.18 CAD

CSE:INNO
Market: CSE
Market Cap: $25.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: InnoCan Pharma signs deal with ADVA Biotechnology to produce...

InnoCann Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has signed a Letter of Intent with ADVA Bio-Technology for exosome manufacturing and development. Bincovich telling Proactive InnoCan intends to load the produced exosomes with...

1 week, 1 day ago

3 min read